These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2393260)

  • 21. Pharmacokinetics and safety of lomefloxacin following multiple doses.
    Hunt TL; Adams MA
    Diagn Microbiol Infect Dis; 1989; 12(2):181-7. PubMed ID: 2752716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraprostatic distribution of lomefloxacin following multiple-dose administration.
    Kovarik JM; de Hond JA; Hoepelman IM; Boon T; Verhoef J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2398-401. PubMed ID: 2088193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lomefloxacin concentrations in bone after a single oral dose.
    On A; Nightingale CH; Quintiliani R; Sweeney KR; Pasternak HS; Maderazo EG
    Am J Med; 1992 Apr; 92(4A):15S-17S. PubMed ID: 1316064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of danofloxacin into the respiratory tract tissues and secretions in calves.
    Friis C
    Am J Vet Res; 1993 Jul; 54(7):1122-7. PubMed ID: 8396371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.
    Cook PJ; Andrews JM; Wise R; Honeybourne D; Moudgil H
    J Antimicrob Chemother; 1995 Feb; 35(2):317-26. PubMed ID: 7759395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lomefloxacin concentration in human prostatic tissue following 3-day administration].
    Morita M; Hatakeyama T; Suzuki K
    Hinyokika Kiyo; 1993 Jan; 39(1):97-9. PubMed ID: 7681621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of interaction between lomefloxacin and caffeine in normal volunteers.
    Healy DP; Schoenle JR; Stotka J; Polk RE
    Antimicrob Agents Chemother; 1991 Apr; 35(4):660-4. PubMed ID: 2069371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin.
    Butler T; Cartagenova M; Dunn D
    J Antimicrob Chemother; 1990 Apr; 25(4):629-34. PubMed ID: 2190972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of lomefloxacin on the normal oral and intestinal microflora.
    Edlund C; Brismar B; Nord CE
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):35-9. PubMed ID: 2303064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antibacterial activity of lomefloxacin in the urine during the 4 days following a single 400 mg oral dose].
    Guibert J; Kitzis MD; Acar JF; Masquelier AM; Bellanger B
    Pathol Biol (Paris); 1989 May; 37(5):411-4. PubMed ID: 2506515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
    Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of food on absorption of lomefloxacin.
    Hooper WD; Dickinson RG; Eadie MJ
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1797-9. PubMed ID: 2285293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetic disposition of fluoroquinolones in the lung.
    Wise R; Baldwin DR; Andrews JM; Honeybourne D
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():65-71. PubMed ID: 1664831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration.
    McKellar Q; Gibson I; Monteiro A; Bregante M
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1988-92. PubMed ID: 10428924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of lomefloxacin.
    Leigh DA; Tait S; Walsh B
    J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of lomefloxacin in the treatment of chronic prostatitis.
    Scelzi S; Travaglini F; Nerozzi S; Dominici A; Ponchietti R; Novelli A; Rizzo M
    J Chemother; 2001 Feb; 13(1):82-7. PubMed ID: 11233805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial effects of lomefloxacin in vitro.
    Chambers ST; Peddie BA; Robson RA; Begg EJ; Boswell DR
    J Antimicrob Chemother; 1991 Apr; 27(4):481-9. PubMed ID: 1856127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.